Established in 2015, CStone focuses on immuno-oncology and precision medicines to meet the medical needs of cancer patients in China and globally. With a world-class management team and a pipeline of 15 drug candidates, including immuno-oncology combination therapies, CStone has received nine NDA approvals for four drugs. The company is currently conducting pivotal clinical trials for multiple late-stage candidates. CStone aims to become a globally recognized biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.